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Age-related clonal haemopoiesis (ARCH) in healthy individuals was initially observed through 
an increased skewing in X-chromosome inactivation [1]. More recently, several groups reported 
that ARCH is driven by somatic mutations [2], with the most prevalent ARCH mutations being in 
the DNMT3A and TET2 genes, previously described as drivers of myeloid malignancies. ARCH 
is associated with an increased risk for haematological cancers [2]. ARCH also confers an 
increased risk for non-haematological diseases, such as cardiovascular disease, 
atherosclerosis, and chronic ischemic heart failure, for which age is a main risk factor [3,4]. 
Whether ARCH is linked to accelerated ageing has remained unexplored. The most accurate 
and commonly used tools to measure age acceleration are epigenetic clocks: they are based on 
age-related methylation differences at specific CpG sites [5]. Deviations from chronological age 
towards an increased epigenetic age have been associated with increased risk of earlier 
mortality and agerelated morbidities [5,6]. Here we present evidence of accelerated epigenetic 
age in individuals with ARCH. The Lothian Birth Cohorts (LBCs) of 1921 and 1936 are two 
longitudinal studies of ageing [7]. Participants have been followed up every ~3 years, each for 
five waves, from the age of 70 (LBC1936) and 79 (LBC1921). Participants were community 
dwelling, relatively healthy, and mostly lived in the City of Edinburgh or its surrounding area 
when recruited. Whole-blood DNA methylation levels were assessed using the Illumina 
HumanMethylation450 BeadChip (Supplemental Experimental Procedures). Genomic variants 
were determined in 1,136 LBC participants (n = 870 from wave 1 at mean age 70 years in 
LBC1936; n = 101 and n = 165 at mean ages 79 and 87, respectively, in LBC1921) with whole-
genome sequencing (WGS) and methylation data. WGS data were aligned with Burrows-
Wheeler Aligner and processed for duplicate mapping reads with samblaster (genome coverage 
of 34.3 reads). Single-nucleotide variants and short indels were called with MuTect (v3.8) before 
annotation using the Ensembl Variant Effect Predictor alongside the Cosmic database of coding 
mutations (v86). ARCH variants were classified as per Jaiswal et al. [2]. Epigenetic age 
acceleration was calculated online (https://dnamage. genetics.ucla.edu/home). We considered 
the Intrinsic Epigenetic Age Acceleration (IEAA, hereafter referred to as Horvath age 
acceleration) measure, which is an adapted version of the original Horvath clock that controls 
for white blood cell proportions [6]. Epigenetic age estimates were regressed on chronological 
age to yield age acceleration residuals. Linear regression adjusting for sex, imputed white blood 
cell proportions (monocytes, natural killer (NK), CD4+ T, CD8+ T, and B cells), and methylation 
processing batch was used to determine the association between ARCH status and Age 
Acceleration. All analyses were conducted in R v3.5.0. Of the ten most prevalent ARCH 
mutations [2], we had sufficient sample size and sequencing depth to annotate the top six in the 
LBCs. We identified 73 participants (from 1,136) with ARCH (6%; Figure 1A). The gene-specific 
prevalence ranged between 1 and 36 cases with ARCH-variant allele frequencies ranging from 
0.034 to 0.677 (Figure 1B). Mutations in TET2 were exclusively frameshift and mutations 
detected in JAK2 (all V617F), SF3B1 and TP53 were exclusively missense. ARCH status was 
associated with a significant increase in Horvath age acceleration: the increase was 4.5 (SE 
0.9) years in LBC1936, and 3.7 (SE 1.2) years in LBC1921 (p = 2.3 x 10-6 and 2.5 x 10-3, 
respectively; Figure 1C and Table S1). Compared with non-ARCH carriers, those with TET2 
mutations had a 6.1 (SE 2.2) year and 6.4 (SE 1.9) year increase in Horvath age acceleration in 
LBC1936 and LBC1921 (p = 0.004 and p = 0.001), respectively. Those with Correspondence 
DNMT3A mutations had 3.8 (SE 1.2) years increase in LBC1936, and 3.0 (SE 1.9) years in 
LBC1921 (p = 0.002 and p = 0.11), respectively (Figure 1D). These effect sizes are much larger 
than the sex differences in Horvath age acceleration, which were 1.8 (SE 0.4) years for men in 
LBC1936 (p = 5.1 x 10-5), and 1.0 years (SE 0.8) in LBC1921 (p = 0.18) (Figure 1D and Table 
S1). We also considered age acceleration estimates from four additional epigenetic clocks: 
Extrinsic (Hannum) Epigenetic Age (EEAA) [6], PhenoAge [8], GrimAge [9] and Zhang Age [10] 
(Figure 1E,F and Figure S1A–F). Briefly, ARCH status was linked to increased EEAA, 
PhenoAge, GrimAge and ZhangAge, acceleration in LBC1921 (effect sizes: 1.9 years, 3.7 
years, 2.8 years and 0.8 years with p = 0.16, 0.014, 9.6 x 10-4, and 3.5 x 10-3, respectively). In 
LBC1936 there was a modest association between ARCH and increased EEAA and ZhangAge 
(2.3 years and 0.5 years, p = 0.012 and 4.4 x 10-3) but no association with PhenoAge or 
GrimAge acceleration (p = 0.32 and 0.99, respectively). There was no consistent association 
between ARCH status and white cell count proportions across the two cohorts: a lower 
proportion of NK cells was linked with ARCH carrier status in LBC1936 (odds ratio per SD of cell 
counts, 0.57 95% CI [0.37, 0.84]), while a higher B cell proportion was associated with ARCH 
status in LBC1921 (OR 1.37 [1.01, 1.94]). We observed associations between ARCH and 
epigenetic age acceleration in the independent LBCs of 1921 and 1936, where the WGS data 
and the DNA methylation data were processed together using identical protocols. Although we 
examined multiple epigenetic clocks in relation to ARCH status, it is possible that the effect 
sizes may vary by the quality control approach applied to the methylation data. Additional 
replication from other cohorts would further strengthen the magnitude and generalisability of the 
associations. Our results could indicate ARCH as an underlying cause for systemic ageing, 
explaining its link to non-haematological, age-related diseases.  
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Figure Legend 
A) Oncoplot showing variant types within the ARCH positive subset of the Lothian Birth 
Cohort. This subset represents 73 participants (6% of 1,1136 total) where one or more 
described somatic variants were detected in the six most prevalent ARCH-associated 
genes. 
B) Box and jitter plot describing the distribution of allele frequencies in all detected somatic 
ARCH variants. Genes with a single variant not shown are TP53 and SF3B1 (allele 
frequencies of 0.089 and 0.257, respectively). The overall distribution of allele 
frequencies by LBC cohort (LBC1921/LBC1936) is also displayed. 
C) Scatter plot showing the Horvath age acceleration (IEAA; years) for individual LBC 
participants against the allele frequency of their somatic ARCH variant in both LBC1921 
(orange dots, net 43.7 years; p=2.5x10-3) and LBC1936 (green dots, net 4.5 years; 
p=2.3x10-6) cohorts. Density plot highlighting the shift in distribution of Horvath age 
acceleration between ARCH positive (orange) and negative participant (turquoise) 
groups. Non-ARCH carriers (blue dots). 
D) Plot showing net Horvath (IEAA) age acceleration in ARCH (with 95% confidence 
intervals). The effect of sex (male versus female) on epigenetic ageing within the 
Lothian Birth Cohort is shown for comparison. 
E) Scatter plot showing the Hannum age acceleration (EEAA; years) against the allele 
frequency of their ARCH variants in both LBC1921 (orange dots, net 1.9 years; p=0.16) 
and LBC1936 (green dots, net 2.3 years; p=0.01) cohorts. Density plot highlighting shift 
in distribution of Hannum age acceleration between ARCH positive (orange) and 
negative participant (turquoise) groups. Non-ARCH carriers (blue dots). 
F) Plot showing the net Hannum (EEAA) age acceleration in ARCH (with 95% confidence 
intervals).  The effect of sex (male versus female) on epigenetic ageing within the 
Lothian Birth Cohort is shown for comparison. 
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